|
Charles W. Gorodetzky, MD, PhD, brings 43 years of knowledge and experience in pharmacology, drug development, clinical trials and addiction medicine to his work with Catalyst.
During 21 years at the National Institute on Drug Abuse (NIDA) Addiction Research Center (ARC), Dr. Gorodetzky established and directed the Drug Metabolism and Kinetics Section, publishing approximately 100 papers, as author or co-author, in urine-screening methodology and interpretation, drug metabolism and the human pharmacology of drug abuse. Dr. Gorodetzky has served on numerous committees and boards including the FDA's Drug Abuse Advisory Committee, the Veteran's Administration Subcommittee on Alcoholism and Drug Dependence of the Mental Health and Behavioral Sciences Program Committee, and the Special Action Office for Drug Abuse Prevention.
Dr. Gorodetzky has been directly involved in the clinical development of vigabatrin since 1995.Dr. Gorodetzky left NIDA and joined the pharmaceutical industry in 1984 and worked for the next 21 years in clinical development, holding positions at Burroughs Wellcome, Ciba Geigy, Cygnus Therapeutic Systems, and Hoechst Marion Roussel (HMR, now Sanofi Aventis). In 2005, he retired from Quintiles, Inc., where he was a vice president in the Medical and Scientific Services Department.
Dr. Gorodetzky has been directly involved in the clinical development of vigabatrin since 1995, initially as the primary responsible development person at HMR and then as the primary development person at Quintiles working with HMR in the clinical development of vigabatrin.
For the past several years, as a clinical professor of psychiatry at the University of Missouri Kansas City, Dr. Gorodetzky has participated as a co-principal investigator in the NIDA Methamphetamine Clinical Trials Group.
After obtaining his bachelor of science degree at MIT in 1958, he earned his medical degree at Boston University School of Medicine in 1962 and a doctor of philosophy degree in pharmacology from the University of Kentucky Medical Center in 1975. | 